1. Introduction {#sec1}
===============

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with selective upper and lower motor neuron degeneration ([@bib2], [@bib13]). Although traditionally viewed as a motor neuron disease, nonneuronal supporting cells extensively contribute to motor neuron degeneration ([@bib1], [@bib3]). Oligodendrocytes are such contributing non-neuronal cells, as they degenerate during disease and are replaced by newly formed oligodendrocytes ([@bib5], [@bib10]). However, in both ALS patients and mutant SOD1 mice, these newly formed oligodendrocytes are immature and dysfunctional, as they insufficiently generate myelin basic protein (MBP) and monocarboxylate transporter 1 (MCT-1) ([@bib5], [@bib6], [@bib10]). Consequently, motor neurons lose an important source of structural and trophic support. Therefore, strategies to improve differentiation of oligodendrocyte progenitor cells (OPCs) toward mature and functional oligodendrocytes could be of therapeutic interest in ALS ([@bib11]).

Considerable efforts were made to shed new light on a plethora of factors that regulate oligodendrocyte differentiation ([@bib7]). Different studies showed that Id2 and Notch1 are permissive for OPC expansion and inhibit their differentiation into functionally mature oligodendrocytes ([@bib15], [@bib17]), suggesting their potential involvement in the oligodendrocyte pathology documented in ALS mice ([@bib5], [@bib10]).

In this study, we investigated whether oligodendroglial-specific deletion of these 2 master regulators of oligodendrocyte differentiation, maturation, and functioning could reduce oligodendrocyte pathology and improve disease outcome in ALS mice.

2. Methods {#sec2}
==========

2.1. Transgenic mouse models {#sec2.1}
----------------------------

Human mutant (SOD1^G93A^) and wild-type (SOD1^WT^) SOD1 overexpression mice (\#004435; <https://www.jax.org/strain/004435> and \#002297; <https://www.jax.org/strain/002297>) and Notch1^Lox/Lox^ mice were purchased from the Jackson Laboratory. ID2^Lox/Lox^ mice were described previously ([@bib8]). Platelet-derived growth factor-α receptor (PDGFαR)-CreER mice ([@bib4]) were kindly donated by Dwight E. Bergles (Johns Hopkins School of Medicine, Baltimore). All mice were maintained on a C57Bl6J background, and littermate controls were used for this study. Cre-mediated recombination was induced at P60 by administering tamoxifen as described previously ([@bib10]). The use and maintenance of all the mice used in this study was approved by the ethical committee of the University of Leuven, Belgium.

2.2. Motor performance, disease onset, and end-point determination {#sec2.2}
------------------------------------------------------------------

Motor performance and disease onset were assessed by the hanging grid test, as described previously ([@bib12]). End-stage was determined as described previously ([@bib14]).

2.3. Immunoblot analysis {#sec2.3}
------------------------

Protein lysates (30 μg) were loaded on a 10% (for MCT-1) or 15% (for MBP) SDS--polyacrylamide gel (SDS-PAGE) and processed as described previously ([@bib10]). Following primary antibodies were used: anti-MBP (goat, 1/10,000; Santa Cruz, RRID: [AB_648794](http://AB_648794){#interref0010}), anti-MCT-1 (chicken, 1/1000; Millipore, RRID: [AB_90565](http://AB_90565){#interref0015}), and anti-GAPDH (mouse, 1/2000; Ambion, RRID: [AB_437392](http://AB_437392){#interref0020}).

3. Results {#sec3}
==========

3.1. Disease outcome is not improved in ALS mice upon oligodendroglial deletion of Id2 or Notch1 {#sec3.1}
------------------------------------------------------------------------------------------------

To evaluate if oligodendroglial-specific deletion of Id2 or Notch1 could reduce oligodendrocyte pathology and improve disease outcome in ALS mice, we crossbred Id2^Lox/Lox^ or Notch1^Lox/Lox^ mice to PDGFαR-CreER and SOD1^G93A^ mice. The specificity of the PDGFαR promoter--driven gene excision and the recombination efficiency obtained with Id2^Lox/Lox^ or Notch1^Lox/Lox^ mice were proven to be as expected, and no significant upregulation of the other Id or Notch molecules was seen (see [Supplementary Results](#appsec1){ref-type="sec"} and [Supplementary Figures 1 and 2](#appsec1){ref-type="sec"}). In the triple transgenic offspring, motor performance, determined by the hanging grid test ([Fig. 1](#fig1){ref-type="fig"}A and D) and the rotarod test ([Supplementary Figure 3A and C](#appsec1){ref-type="sec"}), and body weight ([Supplementary Figure 3B and D](#appsec1){ref-type="sec"}) were evaluated throughout the course of disease. For none of these parameters, a significant improvement was observed upon deletion of Id2 or Notch1 compared to control SOD1^G93A^ mice. Neither was disease onset delayed ([Fig. 1](#fig1){ref-type="fig"}B and E), nor was survival affected ([Fig. 1](#fig1){ref-type="fig"}C and F). Overall these data implicate that oligodendrocytic ablation of Id2 or Notch1 could not improve disease outcome in the SOD1^G93A^ mouse model.Fig. 1Disease outcome is not altered upon oligodendroglial-specific deletion of Id2 or Notch1 in ALS mice. (A, D) Motor performance of SOD1^G93A^ mice assessed by the hanging grid test upon oligodendroglial deletion of (A) Id2 or (D) Notch1 (2-way ANOVA: *p* \> 0.05). (B, E and C, F) Kaplan Meier curves displaying (B, E) disease onset determined by failure on the hanging grid test and (C, F) survival in SOD1^G93A^ mice with selective oligodendroglial deletion of (B, C) Id2 or (E-F) Notch1 compared to control SOD1^G93A^ mice (Log-rank Mantel-Cox test: *p* \> 0.05). For Id2 deletion: G93A = SOD1^G93A^ (n = 30--32), ID2+/− = ID2^Lox/−^ PDGFαR-CreER SOD1^G93A^ (n = 15--16), and ID2−/− = Id2^Lox/Lox^ PDGFαR-CreER SOD1^G93A^ (n = 17--19). For Notch1 deletion: G93A = SOD1^G93A^ (n = 9), Notch1+/− = Notch1^Lox/−^ PDGFαR-CreER SOD1^G93A^ (n = 8--9), and NOTCH1−/− = Notch1^Lox/Lox^ PDGFαR-CreER SOD1^G93A^ (n = 9--12). Abbreviation: HW, hanging wire.

3.2. Oligodendroglial deletion of Id2 or Notch1 does not improve oligodendrocyte dysfunction in ALS mice {#sec3.2}
--------------------------------------------------------------------------------------------------------

MCT-1 and MBP are generally known as markers to assess terminally differentiated and functional oligodendrocytes in ALS ([@bib5], [@bib10]). We evaluated the expression of both proteins in the lumbar spinal cord of end-stage SOD1^G93A^ mice in which Id2 or Notch1 were selectively removed from the oligodendroglial cells and compared it to control SOD1^G93A^ mice and age-matched SOD1^WT^ mice. We found that deleting Id2 or Notch1 is insufficient to correct MBP and MCT-1 levels ([Fig. 2](#fig2){ref-type="fig"}). In contrast to what has been suggested before ([@bib9], [@bib15], [@bib17]), our data indicate that deleting the differentiation inhibitors Id2 or Notch1 from OPCs is not sufficient to correct differentiation and functioning of the oligodendrocytes, at least in this ALS mouse model.Fig. 2Oligodendrocyte dysfunction is not rescued following oligodendrocytic Id2 or Notch1 deletion (A, D). Representative Western blots showing protein levels of MBP and MCT-1 at disease end-stage in the spinal cord of (A) Id2- or (D) Notch1-deleted mice and controls compared to age-matched SOD1^WT^ mice. (B, C, E, F) Quantification of the Western blot experiments shown in (A,D). One-way ANOVA: \* *p* \< 0.05, \*\* *p* \< 0.01, ● = 0.064 compared to age-matched SOD1^WT^ mice, n = 5--10 mice per group. WT = SOD1^WT^, G93A = SOD1^G93A^, ID2+/− = Id2^Lox/−^ PDGFαR-CreER SOD1^G93A^, ID2−/− = ID2^Lox/Lox^ PDGFαR-CreER SOD1^G93A^, NOTCH1+/− = Notch1^Lox/−^ PDGFαR-CreER SOD1^G93A^, and NOTCH1−/− = Notch1^Lox/Lox^ PDGFαR-CreER SOD1^G93A^. Abbreviations: MBP, myelin basic protein, ANOVA, analysis of variance; WT, wild-type.

4. Discussion {#sec4}
=============

Strong evidence suggests that degeneration of oligodendrocytes and improper replacement of the lost cells by newly formed immature and dysfunctional oligodendrocytes substantially contribute to the degeneration of the motor neurons ([@bib5], [@bib10]). We evaluated the potential of Id2 and Notch1, 2 master modulators of oligodendrocyte differentiation, maturation, and functioning ([@bib16], [@bib17]), to overcome the oligodendrocyte pathology seen in ALS. Neither deleting Id2 nor Notch1 specifically in the OPCs and their progeny improved oligodendrocyte differentiation and functioning and consequently did not result in a beneficial effect on disease onset, motor performance, or survival in this ALS mouse model. It obviously remains possible that modulators of oligodendrocyte differentiation and maturation other than Id2 and Notch1, such as Wnt-signaling, Nogo-A, Id4, and human endogenous retroviruses, can be of particular importance to overcome the oligodendroglial pathology seen in ALS ([@bib9]).
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Appendix A. Supplementary data {#appsec1}
==============================

Supplementary Figure 1PDGFαR-CreER induces recombination in oligodendroglial cells. (A) Immunofluorescent staining of YFP (with an anti-GFP antibody) in combination with (A) the OPC marker NG2 and (B) the oligodendrocyte marker CC1 in the ventral horn of the lumbar spinal cord from Rosa-^Lox^STOP^Lox^-YFP PDGFαR-CreER mice (YFP^+/+^ PDGFαR-CreER + Tx) and Rosa-^Lox^STOP^Lox^-YFP mice (YFP^+/+^ + Tx), both receiving tamoxifen (Tx), and Rosa-^Lox^STOP^Lox^-YFP PDGFαR-CreER mice not receiving tamoxifen (YFP^+/+^ PDGFαR-CreER − Tx). Arrowheads indicate nonspecific expression of YFP upon recombination in cells other that NG2^+^ OPCs. Arrows indicate nonspecific expression of YFP upon recombination in CC1^+^ oligodendrocytes. (C) Quantification of the percentage of NG2^+^ OPCs expressing YFP, reflecting OPC-specific recombination. (D) Quantification of the percentage of CC1^+^ oligodendrocytes expressing YFP, reflecting nonspecific recombination in oligodendrocytes.Supplementary Figure 2Highly efficient recombination was observed in Id2^Lox/Lox^ or Notch1^Lox/Lox^ x CAGG-CreER mice, without compensatory mRNA upregulation of other Id or Notch family members. (A--D) mRNA expression levels of (A) *Id1*, (B) *Id2*, (C) *Id3*, and (D) *Id4* were determined by RT-PCR in the lumbar spinal cord upon ubiquitous Id2 deletion. Expression data were normalized to *Polr2a*, *Gapdh,* and *Yhwaz* (TaqMan) or *Fbxo38* and *Actin* (SYBR Green). (E--H) mRNA expression levels of (E) *Notch1* (F) *Notch2* (G) *Notch3*, and (H) *Notch4* were determined by RT-PCR in the lumbar spinal cord upon ubiquitous Notch1 deletion. Expression data were normalized to *Hprt* and *Polr2a* (TaqMan). For Id2 deletion: CTRL = CAGG-CreER, ID2+/− = Id2^Lox/−^ CAGG-CreER, and ID2−/− = Id2^Lox/Lox^ CAGG-CreER mice. For Notch1 deletion: CTRL = Notch1^Lox/Lox^, NOTCH1+/− = Notch1^Lox/−^ CAGG-CreER, and NOTCH1−/− = Notch1^Lox/Lox^ CAGG-CreER. One-way ANOVA: \* *p* \< 0.05, \*\* *p* \< 0.01, n = 3 mice per group.Supplementary Figure 3Disease outcome is not altered upon oligodendroglial Id2 or Notch1 deletion in ALS mice. (A, C) Graphs representing rotarod performance of SOD1^G93A^ mice with oligodendrocytic deletion of (A) Id2 or (C) Notch1 during disease progression compared to control SOD1^G93A^ mice (2-way ANOVA: *p* \> 0.05). (B, D) Monitoring of body weight during disease progression upon selective removal of (B) Id2 or (D) Notch1 in oligodendroglial cells compared to control SOD1^G93A^ mice (2-way ANOVA: *p* \> 0.05). For Id2 deletion: G93A = SOD1^G93A^ (n = 30--32), ID2+/− = ID2^Lox/−^ PDGFαR-CreER SOD1^G93A^ (n = 15--16), and ID2−/− = ID2^Lox/Lox^ PDGFαR-CreER SOD1^G93A^ (n = 17--19). For Notch1 deletion: G93A = SOD1^G93A^ (n = 9), NOTCH1+/− = Notch1^Lox/−^ PDGFαR-CreER SOD1^G93A^ (n = 9), and NOTCH1−/− = Notch1^Lox/Lox^ PDGFαR-CreER SOD1^G93A^ (n = 12).Supplementary Data
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